Skin Cancer and Hyperthermia and Radiotherapy

Who May Qualify: - Personally signed and dated written willing to sign a consent form - diagnosed by tissue sample (biopsy-confirmed) invasive non-melanoma skin cancer (NMSC), including basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) of any differentiation - ≥ T2 (TNM Classification 8th Edition) - Tumor thickness up to 2cm (Maximum Depth invasion and/or exophytic growth, measured on pathology report or imaging) - Local recurrence allowed, if primary treatment longer ago than 6 months (after primary treatment other than radiotherapy (RT)) - Age ≥ 65 years - Eastern Cooperative Oncology Group (ECOG) performance status 0-2, with a life expectancy of more than 6 months - Presentation at the Swiss Hyperthermia Network (SHN) tumor conference mandatory Who Should NOT Join This Trial: - Other histology than BCC or SCC - T1 tumor and/or N+ (according to TNM classification 8th edition) - Tumors after resection (R1 or R2 as well as adjuvant indication) - Tumor invasion into critical areas - Several lesions exceeding the capacity of one treatment/radiation field (multiple lesions within one treatment field are acceptable) - Previous (one month) or concurrent Chemo- or Immunotherapy - Patients with connective tissue disorders (e.g. Sclerodermia, Lupus erythematodes) - Lesions inside or in proximity (within 3cm) previously irradiated area - Medical immunosuppression - wIRA-specific exclusion criteria - Tattoos in irradiated area - Increased photosensitivity (either due to simultaneous treatment with photosensitivity-enhancing medications or conditions such as porphyria) Always talk to your doctor about whether this trial is right for you.